Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL936947 | 1.00 | NR1I2 (0.37) | NR1I2CYP2E1 | |
| SCHEMBL2220415 | 1.00 | NR1I2 (0.37) | NR1I2CYP2E1 | |
| SCHEMBL12444738 | 0.96 | NR1I2 (0.34) | NR1I2CYP2E1 | |
| SCHEMBL2219526 | 0.92 | NR1I2 (0.37) | NR1I2CYP2E1 | |
| SCHEMBL9957527 | 0.92 | NR1I2 (0.37) | NR1I2CYP2E1 | |
| SCHEMBL12444690 | 0.92 | NR1I2 (0.37) | NR1I2CYP2E1 | |
| SCHEMBL14817014 | 0.92 | NR1I2 (0.37) | NR1I2CYP2E1 | |
| SCHEMBL13822270 | 0.92 | NR1I2 (0.37) | NR1I2CYP2E1 | |
| SCHEMBL17237532 | 0.91 | NR1I2 (0.45) | NR1I2CYP2E1 | |
| SCHEMBL9965182 | 0.88 | RAF1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2709613-B2 | METHODS FOR TREATING HCV | GILEAD PHARMASSET LLC (US) | 2020-08-12 | — | — | EP | disclosed |
| EP-2709613-B2 | METHODS FOR TREATING HCV | GILEAD PHARMASSET LLC (US) | 2020-08-12 | — | — | EP | disclosed |
| US-10456414-B2 | Methods for treating HCV | GILEAD PHARMASSET LLC (US) | 2019-10-29 | — | — | US | disclosed |
| US-10456414-B2 | Methods for treating HCV | GILEAD PHARMASSET LLC (US) | 2019-10-29 | — | — | US | disclosed |
| EP-2709613-B1 | METHODS FOR TREATING HCV | GILEAD PHARMASSET LLC (US) | 2017-11-29 | — | — | EP | disclosed |
| EP-2709613-B1 | METHODS FOR TREATING HCV | GILEAD PHARMASSET LLC (US) | 2017-11-29 | — | — | EP | disclosed |
| US-20170189439-A1 | METHODS FOR TREATING HCV | GILEAD SCIENCES, INC. | 2017-07-06 | — | — | US | disclosed |
| US-20170189439-A1 | METHODS FOR TREATING HCV | GILEAD SCIENCES, INC. | 2017-07-06 | — | — | US | disclosed |
| US-20170189439-A1 | METHODS FOR TREATING HCV | GILEAD SCIENCES, INC. | 2017-07-06 | — | — | US | disclosed |
| US-20170042961-A1 | METHODS FOR TREATING HCV | GILEAD PHARMASSET LLC | 2017-02-16 | — | — | US | disclosed |
| US-20130273005-A1 | METHODS FOR TREATING HCV | GILEAD SCIENCES, INC. (US) | 2013-10-17 | — | — | US | disclosed |
| US-20130273005-A1 | METHODS FOR TREATING HCV | GILEAD SCIENCES, INC. (US) | 2013-10-17 | — | — | US | disclosed |
| US-20130243726-A1 | METHODS FOR TREATING HCV | GILEAD PHARMASSET LLC (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130243726-A1 | METHODS FOR TREATING HCV | GILEAD PHARMASSET LLC (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130243726-A1 | METHODS FOR TREATING HCV | GILEAD PHARMASSET LLC (US) | 2013-09-19 | — | — | US | disclosed |
| US-8513298-B2 | Inhibitors of flaviviridae viruses | GILEAD SCIENCES, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| WO-2013040492-A2 | METHODS FOR TREATING HCV | GILEAD SCIENCES, INC. (US) | 2013-03-21 | — | — | WO | disclosed |
| WO-2012087596-A1 | COMBINATIONS FOR TREATING HCV | GILEAD SCIENCES, INC. (US) | 2012-06-28 | — | — | WO | disclosed |
| WO-2012087596-A1 | COMBINATIONS FOR TREATING HCV | GILEAD SCIENCES, INC. (US) | 2012-06-28 | — | — | WO | disclosed |
| US-20110178129-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES, INC. (US) | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130243726-A1 | METHODS FOR TREATING HCV | HAVCR2, DHFR, HCCS | NR1I2 2775/4885CYP2E1 964/4885 |
| US-10456414-B2 | Methods for treating HCV | HAVCR2, HCCS, LIPC | NR1I2 3001/4885CYP2E1 834/4885 |
| US-20130273005-A1 | METHODS FOR TREATING HCV | HAVCR2, HCCS, LIPC | NR1I2 3001/4885CYP2E1 834/4885 |
| US-20170189439-A1 | METHODS FOR TREATING HCV | HAVCR2, HCCS, LIPC | NR1I2 3001/4885CYP2E1 834/4885 |
| US-20170042961-A1 | METHODS FOR TREATING HCV | HAVCR2, HCCS, LIPC | NR1I2 3001/4885CYP2E1 834/4885 |
| US-20110178129-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | HAVCR2, CYP2F1, CYP4F3 | NR1I2 88/4885CYP2E1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.